Fig. 1

ROC curves. a ROC curve for the value of CA-125 in predicting cytoreduction. The AUC was 76.7% (CI 67.8–85.6%, p = 0.000), implying that CA-125 can predict cytoreduction correctly in 84 patients out of a total of 109 patients. b ROC curve for the value of FASN in predicting cytoreduction. The AUC was 65.3% (CI 54.8–75.8%, p = 0.006), implying that FASN can predict cytoreduction correctly in 71 patients out of a total of 109 patients. c ROC curve for the value of GLS in predicting cytoreduction. The AUC was 74.1% (CI 64.6–83.7%, p = 0.0000), implying that GLS can predict cytoreduction correctly in 81 patients out of a total of 109 patients. d ROC curve for the value of FASN and CA-125 in predicting cytoreduction. The AUC was 76.9% (CI 68.1–85.8%, p = 0.0000), implying that FASN and CA-125 can predict cytoreduction correctly in 84 patients out of a total of 109 patients. e ROC curve for the value of GLS and CA-125 in predicting cytoreduction. The AUC was 85.4% (CI 78.4–92.3%, p = 0.0000), implying that GLS and CA-125 can predict cytoreduction correctly in 91 patients out of a total of 109 patients. f ROC curve for the value CA-125, FASN and GLS in predicting ytoreduction. The AUC was 87.7% (CI 81–94.4%, p = 0.0000), implying that CA-125, FASN and GLS can predict cytoreduction correctly in 96 patients out of a total of 109 patients